- Home
- CCEL vs CUE Comparison
CCEL vs CUE Comparison
Compare CCEL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- CUE
- Stock Information
- Founded
- CCEL 1989
- CUE 2014
- Country
- CCEL United States
- CUE United States
- Employees
- CCEL N/A
- CUE N/A
- Industry
- CCEL Managed Health Care
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- CUE Health Care
- Exchange
- CCEL Nasdaq
- CUE Nasdaq
- Market Cap
- CCEL 51.9M
- CUE 58.9M
- IPO Year
- CCEL 1997
- CUE 2018
- Fundamental
- Price
- CCEL $5.12
- CUE $0.64
- Analyst Decision
- CCEL Strong Buy
- CUE Strong Buy
- Analyst Count
- CCEL 1
- CUE 3
- Target Price
- CCEL $8.50
- CUE $3.00
- AVG Volume (30 Days)
- CCEL 10.1K
- CUE 163.7K
- Earning Date
- CCEL 07-14-2025
- CUE 05-12-2025
- Dividend Yield
- CCEL 7.81%
- CUE N/A
- EPS Growth
- CCEL N/A
- CUE N/A
- EPS
- CCEL 0.01
- CUE N/A
- Revenue
- CCEL $32,102,750.00
- CUE $7,991,000.00
- Revenue This Year
- CCEL $2.49
- CUE N/A
- Revenue Next Year
- CCEL $0.95
- CUE $25.99
- P/E Ratio
- CCEL $321.51
- CUE N/A
- Revenue Growth
- CCEL 2.33
- CUE 13.83
- 52 Week Low
- CCEL $4.75
- CUE $0.45
- 52 Week High
- CCEL $9.43
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- CCEL 48.65
- CUE 38.40
- Support Level
- CCEL $4.79
- CUE $0.61
- Resistance Level
- CCEL $5.15
- CUE $0.71
- Average True Range (ATR)
- CCEL 0.17
- CUE 0.06
- MACD
- CCEL 0.05
- CUE -0.00
- Stochastic Oscillator
- CCEL 63.79
- CUE 20.67
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.